Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan in AML and MDS
NCT02319369Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milademetan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at Cycle 1 and Treatment-emergent Adverse Events. Started Nov 2014; status: terminated.
02
Drugs
milademetan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02319369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319369.